CEE 04421

Drug Profile

CEE 04421

Alternative Names: Analgesic tripeptide (CEE 04421) - CeNeS

Latest Information Update: 12 Sep 2002

Price : $50

At a glance

  • Originator National Institute for Biological Standards and Controls; University of Sao Paulo
  • Developer BTG; CeNeS Pharmaceuticals
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Neuropathic pain; Postoperative pain

Most Recent Events

  • 12 Sep 2002 Discontinued - Preclinical for Inflammation in United Kingdom (PO)
  • 12 Sep 2002 Discontinued - Preclinical for Neuropathic pain in United Kingdom (PO)
  • 12 Sep 2002 Discontinued - Preclinical for Postoperative pain in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top